Oncology

PARP inhibitors used alongside immunotherapy may help stimulate the immune response to cancer cells by attracting immune cells to the tumor.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, talks about new therapeutic developments going on within the prostate cancer space.

With this approval, atezolizumab plus nab-paclitaxel is the first cancer immunotherapy regimen to be approved for breast cancer.

Atezolizumab (Tecentriq) plus chemotherapy is approved under the FDA’s Accelerated Approval Program, which allows conditional approval of a medicine that fills an unmet medical need for a serious or life-threatening disease or condition.

Patient-driven recommendations to reduce breast cancer-related economic burden could be key to shaping policies and interventions.

Venetoclax (Venclexta) plus obinutuzumab (Gazyva) is being developed for patients with previously-untreated chronic lymphocytic leukemia and co-existing medical conditions.

Feel More Like You was developed in collaboration with Look Good, Feel Better Foundation, the leading cancer support organization focusing attention on the appearance and beauty needs of cancer patients, and Cancer Support Community, the largest professionally led, nonprofit network of cancer support worldwide.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the rapidly changing oncology market and what to look for in the drug pipeline.

Top news of the week from Specialty Pharmacy Times.

Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) is indicated for subcutaneous administration in certain patients with HER2-positive early and metastatic breast cancer.

Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) is indicated for subcutaneous administration in certain patients with HER2-positive early and metastatic breast cancer.

Top news of the day from across the health care landscape.

The new class of smart drugs has the ability to bring the toxic payload directly to the cancer cells.

This study demonstrates the significance and efficacy of breast cancer screenings for prevention and early intervention.

The FDA approved trifluridine/tipiracil (Lonsurf, Taiho Oncology), also known as TAS-102, as a treatment for certain adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

New research supports the use of direct-acting antiviral therapy for all individuals with chronic hepatitis C infection.

Translational study of breast cancer therapy sought to ‘take research from bench to bedside.’

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

The trial evaluated margetuximab compared with trastuzumab, in combination with chemotherapy, for the treatment of HER 2-positive breast cancer.

Top news of the day across the health care landscape.

If approved, apalutamide (Erleada) plus androgen deprivation therapy would offer an additional treatment option for patients with metastatic castration-sensitive prostate cancer.

The economics of one and done gene therapies dictate a revenue model that requires outcomes-based risk.

Ado-trastuzumab emtansine (Kadcyla) is currently approved for the treatment of patients with HER-2 positive metastatic breast cancer who previously received trastuzumab and a taxane.

The risk of a solid subsequent malignant neoplasm is elevated in survivors of childhood Hodgkin lymphoma, according to an extended follow-up of more than 25 years.

Researchers at University of Texas Health Science Center at San Antonio studied 28,000 childhood cancer survivors to determine similarities in long-term effects for various chemotherapies.

HIV-positive patients with hepatocellular carcinoma had an adjusted 24% increased hazard of death compared to their HIV-negative peers.